Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents


Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and activities of transcriptional factors involved in both cancer initiation and progression through alteration of either DNA or the structural components of chromatin. Recently, the role of gene repression through modulation such as acetylation in cancer patients has been… (More)
DOI: 10.1186/1756-8722-3-5


6 Figures and Tables